Cargando…
Reversing tozasertib resistance in glioma through inhibition of pyruvate dehydrogenase kinases
Acquired resistance to conventional chemotherapeutic agents limits their effectiveness and can cause cancer treatment to fail. Because enzymes in the aurora kinase family are vital regulators of several mitotic events, we reasoned that targeting these kinases with tozasertib, a pan‐aurora kinase inh...
Autores principales: | Jane, Esther P., Premkumar, Daniel R., Rajasundaram, Dhivyaa, Thambireddy, Swetha, Reslink, Matthew C., Agnihotri, Sameer, Pollack, Ian F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732347/ https://www.ncbi.nlm.nih.gov/pubmed/34058053 http://dx.doi.org/10.1002/1878-0261.13025 |
Ejemplares similares
-
ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib
por: Michaelis, Martin, et al.
Publicado: (2015) -
Targeting mitochondrial energetics reverses panobinostat‐ and marizomib‐induced resistance in pediatric and adult high‐grade gliomas
por: Jane, Esther P., et al.
Publicado: (2023) -
Pyruvate Dehydrogenase Kinase as a Potential Therapeutic Target for Malignant Gliomas
por: Jha, Mithilesh Kumar, et al.
Publicado: (2013) -
RIPK1-dependent cell death: a novel target of the Aurora kinase inhibitor Tozasertib (VX-680)
por: Martens, Sofie, et al.
Publicado: (2018) -
Transcriptional Regulation of Pyruvate Dehydrogenase Kinase
por: Jeong, Ji Yun, et al.
Publicado: (2012)